Cryoport, Inc. (NASDAQ:CYRX) CFO Sells $18,925.66 in Stock

Cryoport, Inc. (NASDAQ:CYRX) CFO Robert Stefanovich sold 1,079 shares of the company’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $17.54, for a total transaction of $18,925.66. Following the completion of the transaction, the chief financial officer now owns 128,333 shares of the company’s stock, valued at approximately $2,250,960.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Robert Stefanovich also recently made the following trade(s):

• On Friday, March 15th, Robert Stefanovich sold 1,035 shares of Cryoport stock. The stock was sold at an average price of $15.43, for a total transaction of $15,970.05.
• On Monday, March 11th, Robert Stefanovich sold 1,119 shares of Cryoport stock. The stock was sold at an average price of $16.35, for a total value of $18,295.65.

Cryoport Price Performance

Shares of NASDAQ CYRX opened at $17.70 on Friday. The stock has a fifty day moving average price of $16.02 and a 200 day moving average price of $14.40. Cryoport, Inc. has a 12-month low of $9.00 and a 12-month high of $24.30. The company has a current ratio of 11.73, a quick ratio of 11.16 and a debt-to-equity ratio of 0.82.

Wall Street Analyst Weigh In

CYRX has been the subject of a number of analyst reports. UBS Group boosted their price objective on shares of Cryoport from $14.50 to $17.00 and gave the company a “neutral” rating in a research report on Friday, March 15th. Needham & Company LLC dropped their price target on shares of Cryoport from $19.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, March 13th. Finally, Stephens reissued an “equal weight” rating and set a $17.00 price objective on shares of Cryoport in a research note on Wednesday, March 13th. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $18.29.

Institutional Trading of Cryoport

Large investors have recently modified their holdings of the business. Cadian Capital Management LP boosted its holdings in Cryoport by 298.2% in the third quarter. Cadian Capital Management LP now owns 2,656,739 shares of the company’s stock worth $36,424,000 after purchasing an additional 1,989,598 shares during the period. Morgan Stanley raised its stake in Cryoport by 431.2% during the 3rd quarter. Morgan Stanley now owns 1,525,079 shares of the company’s stock valued at $20,909,000 after acquiring an additional 1,237,953 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in Cryoport by 487.7% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,393,156 shares of the company’s stock worth $21,580,000 after acquiring an additional 1,156,106 shares during the period. Massachusetts Financial Services Co. MA increased its holdings in shares of Cryoport by 46.9% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,992,895 shares of the company’s stock valued at $30,870,000 after purchasing an additional 636,395 shares during the period. Finally, Invesco Ltd. raised its stake in shares of Cryoport by 17.7% during the first quarter. Invesco Ltd. now owns 3,228,313 shares of the company’s stock valued at $112,700,000 after purchasing an additional 485,972 shares in the last quarter. 92.90% of the stock is currently owned by institutional investors and hedge funds.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.